Vanguard Capital Management
EWTX icon

Vanguard Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Vanguard Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157M Buy
3,860,670
+72,509
+2% +$2.5M ﹤0.01% 1299
2026
Q1 		$119M Buy
+3,788,161
New +$109M ﹤0.01% 1371

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management's EWTX Position: Q2 2026 in Review

Vanguard Capital Management increased its Edgewise Therapeutics (EWTX) stake by 1.9% in Q2 2026, buying an estimated $2.5M and bringing the position to 3,860,670 shares worth $157M. The position accounts for ﹤0.01% of the portfolio, ranked #1299.

Vanguard Capital Management first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 224 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Vanguard Capital Management held 3,860,670 shares of Edgewise Therapeutics worth $157M as of Q2 2026.
  • Vanguard Capital Management bought 72,509 Edgewise Therapeutics shares in Q2 2026, an estimated $2.5M.
  • Edgewise Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1299 holding.
  • Vanguard Capital Management first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 224 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.